PRN — Profound Medical Income Statement
0.000.00%
Last trade - 00:00- CA$229.83m
- CA$187.23m
- $10.68m
Annual income statement for Profound Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.3 | 6.87 | 6.68 | 7.2 | 10.7 |
| Cost of Revenue | |||||
| Gross Profit | 3.47 | 2.95 | 3.02 | 4.31 | 7.04 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 26.2 | 37.2 | 38.8 | 35.9 | 43.7 |
| Operating Profit | -18.9 | -30.3 | -32.1 | -28.7 | -33.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21.6 | -30.6 | -28.4 | -28.5 | -27.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -21.6 | -30.7 | -28.7 | -28.3 | -27.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -21.6 | -30.7 | -28.7 | -28.3 | -27.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -21.6 | -30.7 | -28.7 | -28.3 | -27.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.26 | -1.5 | -1.3 | -1.34 | -1.12 |